As the panelists conclude their discussion about systemic lupus erythematosus (SLE) and hemophilia, they share their perspectives about the Affordable Care Act and its potential.
Patrick F. Fogarty, MD, Hugh Fatodu, RPh, MBA, and Maria Lopes, MD, MS, raise concerns about the affordability of healthcare.
Dr Fogarty hopes that despite high treatment costs, patients with hemophilia will have access to necessary drugs and specialty hemophilia treatment centers to receive the care that they require.
Mr Fatodu discusses the need for transparency when pharmaceutical companies review orphan drug prices and explains that the cost of a drug needs to be relative to its value.
Dr Lopes believes that professionals need to work collectively to define a product’s value and determine ways to minimize overall product waste.
Michelle Petri, MD, MPH, recognizes the issues that healthcare professionals face when treating patients with SLE and explains the importance for individualized therapy.
Episode 19 - The Future of SLE and Hemophilia
During this segment, the panelists conclude their discussion about systemic lupus erythematosus and hemophilia. They share their perspectives about the Affordable Care Act and consider how it will impact the future of each disease.
Published Online: January 02, 2014